Xinyi Ding Ding

Dr. Xinyi Ding Ding

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 September 2018 in BMC Ophthalmology
Verified
Journal Article
Open access
PDF file
XDXinyi Ding Ding
Xinyi Ding Ding
RGRuiping Gu
Ruiping Gu
MZMeng Zhang
Meng Zhang
HRHui Ren
Hui Ren
QSQinmeng Shu
Qinmeng Shu
HWHaixiang Wu
Haixiang Wu
Attention is increasingly being given to microglia-related inflammation in neovascular diseases, such as diabetic retinopathy and age-related macular disease. Evidence shows that activated microglia contribute to disruption of the blood–retinal barrier, however, the mechanism is unclear. In this study, we aimed to clarify whether and how microglia affect the function of retinal microvascular endothelial cells (RMECs). We activated microglia by Lipopolysaccharides (LPS) stimulation. After co-culturing static or activated microglia with RMECs using the Transwell system, we evaluated the function of RMECs. Vascular endothelial growth factor-A (VEGF-A) and platelet-derived growth factor-BB (PDGF-BB) levels in the supernatant from the lower chamber were evaluated by ELISA. Angiogenesis, migration, and proliferation of RMECs were assessed by tube formation, wound healing, and WST-1 assays. The expression levels of tight junction proteins (ZO-1 and occludin) and endothelial markers (CD31 and CD34) were examined by Western blot analysis. We successfully established an LPS-activated microglia model and co-culture system of static or activated microglia with RMECs. In the co-culture system, we showed that microglia, especially activated microglia stimulated VEGF-A and PDGF-BB expression, enhanced angiogenesis, migration, proliferation, and permeability, and altered the phenotype of co-cultured RMECs. Microglia, especially activated microglia, play important roles in angiogenesis and maintenance of vascular function hemostasis in the retinal microvasculature. The mechanism needs further investigation and clarification.

27 February 2024 in Inflammation
Verified
Journal Article
Closed access
PDF file
YZYue Zou
Yue Zou
JJJunliang Jiang
Junliang Jiang
YLYunqin Li
Yunqin Li
XDXinyi Ding Ding
Xinyi Ding Ding
FFFang Fang
Fang Fang
LCLing Chen
Ling Chen

16 May 2022 in Vaccines
Verified
Journal Article
Open access
PDF file
XDXinyi Ding Ding
Xinyi Ding Ding
QCQing Chang
Qing Chang
COVID-19 vaccination is considered the most effective and promising approach for the elimination of the SARS-CoV-2 pandemic globally. Although the vaccine has been proven to be safe, as evidenced by the promotion of mass vaccination, new side effects, including several ocular complications that were not described during the experimental stage, are now emerging. In the present study, we report a 33-year-old Chinese man who developed probable Vogt–Koyanagi–Harada (VKH) disease only one day after his first dose of an inactivated COVID-19 vaccine, without any systemic symptoms. His medical history was unremarkable, except for hypertension. Although successfully relieved by oral prednisone, the patient progressed to the chronic stage of VKH disease with ocular depigmentation 4 months after onset. By reviewing similar cases previously reported, we discuss and summarize the common characteristics of VKH disease associated with vaccines against SARS-CoV-2, as well as the possible mechanisms behind this phenomenon. Although the causality is unclear, ophthalmologists and generalists should be aware of this possible ocular adverse effect after COVID-19 vaccination.

14 June 2024 in Ophthalmology Retina
Verified
Journal Article
Closed access
FRFrancesco Romano
Francesco Romano
FVFilippos Vingopoulos
Filippos Vingopoulos
MYMelissa Yuan
Melissa Yuan
XDXinyi Ding Ding
Xinyi Ding Ding
MGMauricio Garcia
Mauricio Garcia
JMJoan Miller
Joan Miller

25 October 2022 in Vaccines
Verified
Journal Article
Open access
PDF file
RHRuyi Han
Ruyi Han
GXGezhi Xu
Gezhi Xu
XDXinyi Ding Ding
Xinyi Ding Ding
With the promotion of mass COVID-19 vaccination in the elimination of the SARS-CoV-2 pandemic, new side effects, including ocular complications, are emerging. In this study, we report on a 62-year-old Chinese man who developed Vogt–Koyanagi–Harada (VKH) disease six days after his third dose of an inactivated COVID-19 vaccine, with a preceding severe headache and tinnitus. His medical history included tuberculosis 20 years prior and hypertension. Systemic prednisone was administered, resulting in completely relieved inflammation and improved visual acuity. Another three and a half months later, the visual acuity of his right eye slightly decreased due to complicated central serous chorioretinopathy (CSC) disease. By gradually replacing prednisone with cyclosporine within 2 months, the subretinal fluid was completely absorbed at the last visit. Steroid-related CSC during the treatment course of VKH disease after COVID-19 vaccination has never been reported before. By reviewing relative literature, we discuss the mechanism of CSC onset in our case and the potential therapeutic strategies. Complicated CSC may develop in the eyes with vaccine-related VKH after steroid treatment. Ophthalmologists should be aware of this condition, carefully distinguish complicated CSC with inflammation relapse, and adjust the medication in a timely manner.

19 August 2025 in Ophthalmology Retina
Verified
Journal Article
Closed access
XDXinyi Ding Ding
Xinyi Ding Ding
JXJia Xu
Jia Xu
FRFrancesco Romano
Francesco Romano
Itika GargItika Garg
Itika Garg
JGJenny Gan
Jenny Gan
JMJoan Miller
Joan Miller